Skip to main content
Clinical Trials/NCT03515057
NCT03515057
Unknown
Not Applicable

Screening for Atrial Fibrillation in an Ambulatory Clinic Population: The VITAL-AF Study

Massachusetts General Hospital1 site in 1 country35,308 target enrollmentJuly 31, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Massachusetts General Hospital
Enrollment
35308
Locations
1
Primary Endpoint
Incident AF during the study period
Last Updated
5 years ago

Overview

Brief Summary

The overall goal of this study is to assess the effectiveness of screening for undiagnosed atrial fibrillation (AF) using simple, efficient, and portable electronic health and mobile technologies in a healthcare system. The investigators propose to perform population-based screening for undiagnosed AF as part of usual care in patients ≥ 65 years when their vital signs are checked (spot-check) at scheduled outpatient visits in adult Massachusetts General Hospital (MGH) primary care clinics. Patients will receive routine care by their primary care provider (PCP) based upon the results of the screening during the visit.

The investigators hypothesize that rates of AF detection among individuals ≥ 65 years in the MGH primary care network will be greater among patients in clinics assigned to the spot-check arm compared to patients in clinics assigned to the usual care arm of the study.

Registry
clinicaltrials.gov
Start Date
July 31, 2018
End Date
October 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Steven A Lubitz

Cardiac Electrophysiologist, Assistant Professor

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients aged 65 years or older
  • Presenting for an outpatient clinic appointment at a participating clinic
  • Visit with a physician, nurse practitioner, or physician's assistant

Exclusion Criteria

  • Have a primary care physician outside of the network
  • Do not visit their primary care practice during the study period

Outcomes

Primary Outcomes

Incident AF during the study period

Time Frame: 12-months

The numerator of the outcome is the number of eligible patients with newly diagnosed AF during the study period. The eligible study population comprising the denominator will be assessed in two ways: (1) the whole population, defined as all patients aged 65 years and older presenting for an outpatient clinic appointment with a participating physician, nurse practitioner, or physician assistant at a study clinic during the enrollment period, and (2) the whole population excluding patients with an AF diagnosis prior to outcome assessment (prevalent AF).

Secondary Outcomes

  • Incident AF associated with a primary care encounter during the study period(12-months)
  • New oral anticoagulation prescription during the study period(12-months)
  • Continued prescription of anticoagulation at 12 months among those started on anticoagulation during the study period(12-months following initial prescription of anticoagulation (ie, up to 24 months after study start))
  • New ischemic stroke within 24-months of the study start(24-months)
  • Major hemorrhage within 24-months of the study start(24-months)

Study Sites (1)

Loading locations...

Similar Trials